7 papers in the library · 475 citations · publishing 2012-2025
The Journal of Clinical Psychiatry October 13, 2025 Pim B. van der Meer, Sebastiaan O Verboeket, Arjen J. C. Slooter et al.
Recent evidence suggests that NMDA receptor antagonists, such as ketamine, may offer benefit in catatonia. This systematic review was conducted to evaluate the efficacy and safety of ketamine and esketamine for catatonia.
Psychedelic Medicine October 8, 2025 Pim B. van der Meer, Nout Schukking, Miranda G. Dik et al.
Background: Psychedelics such as lysergic acid diethylamide (LSD) and psilocybin have shown a beneficial effect on substance use disorder (SUD) symptoms. In this systematic review, we aimed to assess the efficacy and safety of psychoactive tryptamines in patients with an SUD or non-substance-related disorder (i.e., gambling disorder) in order to provide a comprehensive overview of the available...
CNS Drugs October 1, 2024 Anton Gomez-Escolar, Daniel Folch-Sanchez, Joanna Stefaniuk et al. 16 citations
Mental health disorders and substance use disorders (SUDs) in particular, contribute greatly to the global burden of disease. Psychedelics, including entactogens and dissociative substances, are currently being explored for the treatment of SUDs, yet with less empirical clinical evidence than for other mental health disorders, such as depression or post-traumatic stress disorder (PTSD). In this...
Frontiers in Psychiatry February 9, 2023 Kees Kramers, Arnt Schellekens, Metten Somers et al. 119 citations
Background Psychedelic-assisted therapy [e.g., with lysergic acid diethylamide (LSD)] has shown promising results as treatment for substance use disorders (SUDs). Previous systematic reviews assessing the efficacy of psilocybin in SUDs only included clinical trials conducted in the last 25 years, but they may have missed clinical trials assessing the efficacy of psilocybin that were conducted...
Brain Science February 1, 2020 Sanne J. van der Steur, Albert Batalla, Matthijs G. Bossong
Increasing evidence indicates a relationship between cannabis use and psychosis risk. Specific factors, such as determinants of cannabis use or the genetic profile of cannabis users, appear to moderate this association. The present systematic review presents a detailed and up-to-date literature overview on factors that influence the relationship between cannabis use and psychosis risk. A...
Addiction Biology March 3, 2016 Laura Blanco‐Hinojo, Jesus Pujol, Ben J. Harrison et al. 52 citations
Heavy cannabis use is associated with reduced motivation. The basal ganglia, central in the motivation system, have the brain's highest cannabinoid receptor density. The frontal lobe is functionally coupled to the basal ganglia via segregated frontal-subcortical circuits conveying information from internal, self-generated activity. The basal ganglia, however, receive additional influence from...
Current Pharmaceutical Design September 12, 2012 Rocío Martín‐Santos, José Alexandre S. Crippa, Albert Batalla et al. 288 citations
RATIONALE: Animal and humans studies suggest that the two main constituents of cannabis sativa, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) have quite different acute effects. However, to date the two compounds have largely been studied separately. OBJECTIVE: To evaluate and compare the acute pharmacological effects of both THC and CBD in the same human volunteers. METHODS: A...